Week of January 25th, 2021 | Vol. 10, Issue 4
In This Issue
Featured Headlines
Recent Industry Transactions
Industry Trading Comps
Recent Industry Headlines
Market Reports
Upcoming Events

Quick Links

Contact Information
Managing Director
Business Development

Managing Director
Head of M&A and Capital Advisory

Above is an overview of recent industry M&A activity. For additional information, see the charts below or click on the chart above to download complete transaction tables broken out by industry sub sectors.

For more information about our consumer healthcare JV with The Emerson Group, Daybreak Consumer Care, click here.
Recent Materials Providing Insight Into Healthcare Related Industries
Current M&A Pipeline
Representative Current Retained Sell-Side And Partnering Opportunities
Project Trident
Buy-side | Generic Pharma | Manufacturing liquid generics

Project Aspen
Sell-side | CDMO | Multinational CDMO headquartered in US

Project Athena
Sell-side / Licensing | Medical Device | Novel device for pelvic organ prolapse

Project Bulldog
Sell-side | Pharma Services| Life sciences consulting firm
Eli Lilly and Company has successfully completed its $1.04 billion acquisition of Prevail Therapeutics Inc., adding a new modality for drug discovery and development at Lilly, and extending research efforts through the creation of a gene therapy program that will be anchored by Prevail's portfolio of clinical-stage and preclinical neuroscience assets.
"We are pleased to complete the acquisition of Prevail and establish a gene therapy program at Lilly that has the potential to deliver transformative treatments for patients with neurodegenerative diseases such as Parkinson's, Gaucher and dementia," said Mark Mintun, M.D., vice president of pain and neurodegeneration research at Lilly.

An Overview of Transactions Within Market Sub-segments
Below are summaries and charts with the past week's transactions from the different healthcare sectors. For a detailed table showing data for each industry transaction click on any of the charts. Total transaction values are provided in USD millions.
Pharma & Biotech
9 transactions totaling $129 million
Supplies, Equipment & Services
26 transactions totaling $1,360 million
Healthcare IT & Managed Care
6 transactions totaling $1,592 million
Healthcare Facilities & Distributors
7 transactions
Pharma & Biotech
31 transactions totaling $329 million
Supplies, Equipment & Services
19 transactions totaling $549 million
Healthcare IT & Managed Care
11 transactions totaling $58 million
Healthcare Facilities & Distributors
7 transactions totaling $58 million
Pharma & Biotech
40 transactions totaling $4,644 million
Supplies, Equipment & Services
16 transactions totaling $1,142 million
Healthcare IT & Managed Care
0 transactions
Healthcare Facilities & Distributors
1 transaction totaling $160
A Breakdown of Relevant Trading Multiples
Each week, we provide updated trading comps for leading companies from numerous healthcare sub-sectors.
To the right you will see a high-level breakdown of median revenue and EBITDA multiples for each of the specific sub sectors.

For a complete trading comp analysis (including the individual equities that comprise the sub sectors), click on the table. 

Note: data reflects prior week close.
A Sampling of Relevant Industry Headlines from Last Week
Below are snippets from relevant industry news articles from the past week. For additional information or the article's complete text, click the headline link to view the original publication.
January 21, 2021 - Fierce Biotech
On paper, the transaction features a cash payment of $925 million, plus an additional $300 million tied to the achievement of certain commercial milestones. However, Boston Scientific has built up a 22% stake in Preventice, which is expected to lower the net payments to $720 million upfront and about $230 million in milestone money, respectively.

January 20, 2021 - Fierce Pharma
The company is offering 70 million shares on the Nasdaq—slated for the ticker OCDX—that are expected to be priced between $20 and $23 apiece in the coming week. Hitting the midpoint of that range would bestow a market value of $4.9 billion, according to Renaissance Capital.

January 20, 2021 - Fierce Biotech
The $635 million cash deal is expected to be completed by the end of March, with Capsule’s 300 employees slated to join Philips’ connected care division. Capsule’s software-as-a-service offerings are currently used by over 2,800 healthcare organizations globally, with development teams based in the U.S. and France, while its platform can connect to over 940 unique devices.

January 19, 2021 - Contract Pharma
NextPharma offers specialized contract development and manufacturing organization (CDMO) services in oral and topical, including sterile ophthalmic, finished dosage forms. With this intended acquisition, NextPharma plans to develop and broaden its technology offering into lipid based finished dosage forms—softgels and liquid-filled hard capsules—in addition to offering high potency capabilities and New Chemical Entity (NCE) development services to both its existing and new customers.
Welcome to Bourne, let's talk.

Since our founding in 2001, Bourne Partners has remained focused on fulfilling the unique needs of established, middle-market healthcare and pharmaceutical companies across the globe. Our track record includes advising middle market companies in healthcare M&A assignments totaling more than $7 billion, and growing companies into successful and well-positioned pharmaceutical enterprises.